Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Kaskela Law LLC announces that it is investigating eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) on behalf of the company's former employees.

On August 25, 2021, Locust Walk Acquisition Corp. ("Locust Walk"), a publicly traded special purpose acquisition ("SPAC") company, announced that Locust Walk's stockholders had approved of an acquisition of privately held eFFECTOR Therapeutics ("Legacy eFFECTOR"). Locust Walk also announced that, upon the closing of the acquisition, the combined company would be renamed eFFECTOR Therapeutics, Inc. and its common stock would start trading under ticker symbol NASDAQ: EFTR.

In connection with the closing of the acquisition, many of Legacy eFFECTOR's executives and employees had their previously held shares/stock options of privately held Legacy eFFECTOR converted into shares of publicly traded eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR). The investigation seeks to determine whether this share conversion was done in a fair manner and in accordance with the securities laws, or whether former Legacy eFFECTOR shareholders were financially harmed in connection with the conversion.

Former Legacy eFFECTOR employees who had their shares/stock options of privately held Legacy eFFECTOR converted into publicly traded shares of eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 - 0750 or (888) 715 - 1740, or by clicking on the following link (or if necessary, by copying and pasting the link into your browser):

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit .

This notice may constitute attorney advertising in certain jurisdictions.